Bladder cancer stage 0 with carcinoma in situ is the earliest form of this disease, but it requires careful attention and treatment to prevent it from advancing to more dangerous stages.

Understanding Your Treatment Path When Cancer is Found Early

When bladder cancer is caught at stage 0 with carcinoma in situ, the main goal of treatment is to remove the cancer completely and prevent it from returning or spreading deeper into the bladder wall. At this early stage, cancer cells are found only in the inner lining of the bladder and have not invaded the muscle layers, which makes treatment more straightforward than in advanced stages. However, this particular form of stage 0 bladder cancer has a higher tendency to come back after treatment or to progress to more invasive disease compared to other early-stage forms, so ongoing monitoring and sometimes additional therapy are essential parts of the treatment plan.^[1][2]

The treatment approach depends on several factors that your medical team will carefully consider. These include how the cancer cells look under a microscope, the size and number of tumors, and whether this is your first diagnosis or if the cancer has returned after previous treatment. Medical societies and expert panels have developed guidelines to help doctors choose the most effective treatment for each patient’s unique situation. Because stage 0 carcinoma in situ is classified as high-grade bladder cancer, meaning the cells look very abnormal under the microscope, it is treated more aggressively than low-grade stage 0 cancers.^[4][5]

Treatment typically involves a combination of surgical removal of visible cancer and therapy delivered directly into the bladder to kill any remaining cancer cells and reduce the risk of recurrence. Researchers continue to study new ways to treat this early-stage disease, and clinical trials are testing innovative approaches that may offer better outcomes for patients in the future.^[9]

Standard Treatment Approaches

Surgical Removal Through Transurethral Resection

The first step in treating stage 0 bladder cancer with carcinoma in situ is usually a procedure called transurethral resection, often abbreviated as TUR. This is both a diagnostic and a treatment procedure performed by a urologist, a doctor who specializes in diseases of the urinary system. During a TUR, the doctor inserts a thin, lighted tube called a cystoscope into the bladder through the urethra, which is the tube that carries urine out of the body. This allows the doctor to see the lining of the bladder directly and examine any abnormal areas.^[4][16]

Through the cystoscope, the urologist can remove samples of tissue for examination under a microscope or remove visible cancer from the bladder. The procedure also uses electrical energy, called cautery or fulguration, or sometimes laser energy to destroy cancer cells at the site where they are removed. This helps ensure that all visible cancer is eliminated. For stage 0 carcinoma in situ, the doctor performs a biopsy and destroys all visualized cancer during the procedure. The tissue removed is then examined by a pathologist to confirm the diagnosis and determine the grade and exact type of cancer present.^[16][17]

Sometimes, a second TUR procedure may be needed if the first surgery did not remove enough tissue or did not include a sample from the muscle layer of the bladder. This repeat procedure helps ensure that the cancer has not spread deeper than initially thought. If the repeat surgery finds that cancer has invaded the muscle layer, the treatment plan would change because the cancer would then be classified as muscle-invasive bladder cancer, which requires different and more intensive treatment.^[17]

Intravesical Therapy to Prevent Recurrence

Because carcinoma in situ of the bladder has a high likelihood of recurring after surgical removal, nearly all patients receive additional treatment delivered directly into the bladder. This approach is called intravesical therapy, which means the medication is placed inside the bladder rather than being given through the bloodstream. The medicine is delivered through a thin tube called a catheter that is inserted through the urethra into the bladder. The medication stays in the bladder for a period of time, typically one to two hours, allowing it to work directly on any remaining cancer cells in the bladder lining. Patients are usually asked to avoid urinating during this time so the medicine can remain in contact with the bladder wall.^[9][17]

The most common type of intravesical therapy for stage 0 carcinoma in situ is BCG, which stands for Bacillus Calmette-Guérin. BCG is a weakened form of bacteria related to the one that causes tuberculosis. When placed in the bladder, BCG stimulates the body’s immune system to attack and destroy cancer cells. It is considered a form of immunotherapy because it works by activating the patient’s own immune defenses rather than directly killing cancer cells like chemotherapy does. BCG has been used for decades and is highly effective for high-risk stage 0 bladder cancer, including carcinoma in situ.^[9][12][19]

BCG treatment typically begins several weeks after the TUR procedure to allow the bladder to heal. The initial course usually involves weekly treatments for six weeks. After this induction phase, maintenance therapy may be recommended, which involves additional BCG treatments given at regular intervals for up to three years. The schedule for maintenance therapy varies but often includes treatments at three months, six months, and then at six-month intervals for the next two to three years. This prolonged treatment significantly reduces the chance that cancer will return or progress to a more invasive form.^[9][17]

Side effects from BCG therapy are common but usually manageable. Many patients experience bladder irritation symptoms such as frequent urination, urgent need to urinate, burning sensation during urination, and sometimes blood in the urine. These symptoms typically occur within hours after treatment and may last for a day or two. Some patients develop flu-like symptoms including fever, fatigue, and general discomfort. More serious side effects are uncommon but can occur if the BCG bacteria spread beyond the bladder. Patients should contact their doctor immediately if they develop high fever, severe flu-like symptoms that last more than two days, or other concerning symptoms.^[9]

An alternative to BCG is intravesical chemotherapy using drugs such as mitomycin or gemcitabine. These chemotherapy medications work by directly killing cancer cells. Mitomycin has been used for many years and is effective at preventing recurrence of bladder cancer. Gemcitabine is a newer option that has shown good results and may cause fewer side effects than some other chemotherapy drugs. Intravesical chemotherapy is sometimes chosen for patients who cannot tolerate BCG or when BCG is not available. The side effects of intravesical chemotherapy are generally milder than those of BCG and mainly include bladder irritation symptoms similar to a bladder infection.^[9][17]

When Additional Surgery is Needed

For some patients with stage 0 carcinoma in situ, particularly those with multiple tumors or cancer that does not respond to BCG therapy, more extensive surgery may be recommended. This surgery, called a cystectomy, involves removing part or all of the bladder. A radical cystectomy, which removes the entire bladder, may be suggested for very high-risk cases, such as when cancer recurs despite BCG treatment or when cancer cells are detected in certain high-risk locations like the urethra. This is a major surgical procedure that requires reconstruction of the urinary system to allow urine to leave the body through a new pathway.^[9][16][17]

Ongoing Surveillance and Follow-Up

After initial treatment, patients with stage 0 carcinoma in situ require frequent and regular follow-up examinations for many years. This surveillance is crucial because even after successful treatment, the cancer can return, and early detection of recurrence allows for prompt treatment. Follow-up typically includes cystoscopy, where a doctor examines the inside of the bladder with a camera, and urinary cytology, which involves examining urine under a microscope to look for cancer cells. These tests are usually performed every three months during the first year or two after treatment, then less frequently if no cancer is found.^[4][17][21]

If cancer recurs, it is often still at an early stage and can be treated again with TUR and intravesical therapy. However, recurrent cancer may be more aggressive or more likely to progress to invasive disease, so treatment decisions become more complex. Close monitoring allows doctors to detect changes early and adjust the treatment plan as needed.^[4]

Treatment in Clinical Trials

Despite standard treatment with surgery and intravesical BCG or chemotherapy, a significant number of patients with stage 0 carcinoma in situ experience cancer recurrence. Some cancers do not respond well to BCG, and others eventually become resistant to it. Because of these challenges, researchers are actively working to develop new and more effective treatments. Clinical trials offer patients access to these innovative therapies that are not yet available as standard treatment.^[4]

Clinical trials are research studies that evaluate new drugs, new combinations of existing drugs, or new treatment approaches to determine if they are safe and effective. These trials are carefully designed and monitored to protect patient safety while gathering important scientific information. Participation in a clinical trial may provide access to treatments that could work better than current standard therapies, and it also contributes to advancing medical knowledge that will help future patients.^[4]

Clinical trials progress through different phases. Phase I trials focus primarily on safety, testing a new treatment in a small group of people to determine the appropriate dose and identify side effects. Phase II trials involve more patients and aim to see if the treatment shows signs of effectiveness against the cancer while continuing to monitor safety. Phase III trials compare the new treatment directly with the current standard treatment in large groups of patients to determine which approach works better. Trials for bladder cancer are conducted at medical centers throughout the United States, Europe, and other regions around the world.^[9]

For patients with stage 0 bladder cancer that has not responded to BCG treatment or has recurred after BCG, several new treatment options are being explored in clinical trials. These innovative approaches include different types of immunotherapy drugs, new chemotherapy agents, and combination strategies that may work better than existing treatments. While specific drug names and detailed trial results are continuously evolving as research progresses, these studies represent hope for better outcomes and fewer side effects in the future.^[9]

Patients interested in participating in a clinical trial should discuss this option with their doctor, who can help determine if a trial might be appropriate based on the individual’s specific situation, the characteristics of their cancer, and their overall health. Not every patient will be eligible for every trial, as each study has specific requirements about who can participate. However, clinical trials are available for most stages of bladder cancer, including early-stage disease like carcinoma in situ. Your doctor can help you find trials that are accepting patients and explain the potential benefits and risks of participation.^[4][9]

Most common treatment methods

• Surgical removal (Transurethral Resection)
  • Performed using a cystoscope inserted through the urethra to visualize and remove cancer from the bladder lining
  • Uses electrical cautery or laser energy to destroy cancer cells at the removal site
  • May be repeated if initial surgery is inadequate or if muscle layer sampling is needed
  • Serves both diagnostic and therapeutic purposes
• Intravesical BCG immunotherapy
  • Weakened bacteria placed directly into the bladder to stimulate the immune system against cancer cells
  • Initial course typically involves weekly treatments for six weeks
  • Maintenance therapy may continue for up to three years to prevent recurrence
  • Most effective treatment for high-risk stage 0 bladder cancer including carcinoma in situ
  • Common side effects include bladder irritation and flu-like symptoms
• Intravesical chemotherapy
  • Chemotherapy drugs such as mitomycin or gemcitabine placed directly into the bladder
  • Medication remains in bladder for one to two hours to kill cancer cells
  • May be used at the time of surgery or as maintenance therapy
  • Alternative option for patients who cannot tolerate BCG
  • Generally causes milder side effects than BCG, mainly bladder irritation
• Cystectomy (bladder removal surgery)
  • Partial or complete removal of the bladder for cancer that does not respond to other treatments
  • Considered for very high-risk cases or BCG-unresponsive cancer
  • Requires reconstruction of urinary system after bladder removal
  • Major surgical procedure reserved for specific situations
• Surveillance and monitoring
  • Regular cystoscopy examinations to inspect bladder lining
  • Urinary cytology to examine urine for cancer cells
  • Typically performed every three months initially, then less frequently
  • Essential for early detection of cancer recurrence